ArticleThe Journal of allergy and clinical immunology2009

Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis.

Sébastien Conus et al.PubMed ↗Publisher ↗

No numbers read from the abstract.